Susquehanna International Group’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-247,000
| Closed | -$11.7M | – | 12226 |
|
|
2025
Q3 | $11.7M | Sell |
247,000
-293,200
| -54% | -$14.2M | ﹤0.01% | 2842 |
|
|
2025
Q2 | $28.8M | Buy |
540,200
+458,500
| +561% | +$20.8M | ﹤0.01% | 1644 |
|
|
2025
Q1 | $3.31M | Sell |
81,700
-94,400
| -54% | -$4M | ﹤0.01% | 4461 |
|
|
2024
Q4 | $4.9M | Buy |
176,100
+51,600
| +41% | +$1.56M | ﹤0.01% | 3626 |
|
|
2024
Q3 | $3.57M | Buy |
124,500
+9,700
| +8% | +$253K | ﹤0.01% | 4222 |
|
|
2024
Q2 | $2.69M | Sell |
114,800
-50,300
| -30% | -$1.08M | ﹤0.01% | 4509 |
|
|
2024
Q1 | $4.17M | Sell |
165,100
-452,600
| -73% | -$10.9M | ﹤0.01% | 3940 |
|
|
2023
Q4 | $14.4M | Buy |
617,700
+316,000
| +105% | +$6.23M | ﹤0.01% | 2168 |
|
|
2023
Q3 | $15.3M | Buy |
301,700
+151,900
| +101% | +$7.07M | ﹤0.01% | 2056 |
|
|
2023
Q2 | $6.99M | Buy |
149,800
+39,800
| +36% | +$1.82M | ﹤0.01% | 3007 |
|
|
2023
Q1 | $4.21M | Sell |
110,000
-4,900
| -4% | -$218K | ﹤0.01% | 3706 |
|
|
2022
Q4 | $6.3M | Sell |
114,900
-50,900
| -31% | -$2.18M | ﹤0.01% | 2888 |
|
|
2022
Q3 | $5.64M | Buy |
165,800
+154,500
| +1,367% | +$2.36M | ﹤0.01% | 2970 |
|
|
2022
Q2 | $107K | Buy |
+11,300
| New | +$118K | ﹤0.01% | 11410 |
|
|
2021
Q2 | – | Sell |
-14,500
| Closed | -$421K | – | 12491 |
|
|
2021
Q1 | $421K | Buy |
+14,500
| New | +$439K | ﹤0.01% | 9865 |
|
|
2020
Q4 | – | Sell |
-9,400
| Closed | -$289K | – | 10959 |
|
|
2020
Q3 | $289K | Buy |
+9,400
| New | +$329K | ﹤0.01% | 8779 |
|
Other funds holding AKRO
Susquehanna International Group's AKRO Position: Q4 2025 in Review
Susquehanna International Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 50,683 shares — an estimated $2.41M sold.
Susquehanna International Group first reported a position in AKRO in Q1 2020 and held it in 22 quarters. The position peaked at $17.7M in Q3 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Susquehanna International Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Susquehanna International Group sold 50,683 Akero Therapeutics shares in Q4 2025, an estimated $2.41M.
- Susquehanna International Group first reported a position in Akero Therapeutics in Q1 2020 and held it in 22 quarters.
- Susquehanna International Group's Akero Therapeutics position peaked at $17.7M in Q3 2023.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.